"Protein Kinase C beta" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
PKC beta encodes two proteins (PKCB1 and PKCBII) generated by alternative splicing of C-terminal exons. It is widely distributed with wide-ranging roles in processes such as B-cell receptor regulation, oxidative stress-induced apoptosis, androgen receptor-dependent transcriptional regulation, insulin signaling, and endothelial cell proliferation.
| Descriptor ID |
D064546
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.725.049
|
| Concept/Terms |
Protein Kinase C beta2- Protein Kinase C beta2
- PKCbeta2
- Protein Kinase C-beta(II)
- PKCBII
- PKC-beta II
- PKC beta II
- Protein Kinase C beta I
- Protein Kinase C-beta (II)
- PKC beta 2
- beta 2, PKC
- Protein Kinase C beta II
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase C beta".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase C beta".
This graph shows the total number of publications written about "Protein Kinase C beta" by people in this website by year, and whether "Protein Kinase C beta" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 3 | 3 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 0 | 1 | 1 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2019 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Protein Kinase C beta" by people in Profiles.
-
PKC?II-ACSL4 pathway mediating ferroptosis execution and anti-tumor immunity. Cancer Commun (Lond). 2022 07; 42(7):583-586.
-
Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease. Hum Mol Genet. 2019 06 15; 28(12):2014-2029.
-
Protein Kinase C Quality Control by Phosphatase PHLPP1?Unveils Loss-of-Function Mechanism in Cancer. Mol Cell. 2019 04 18; 74(2):378-392.e5.
-
Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol. 2017 06; 18(6):694-704.
-
Prediction of early hepatocellular carcinoma recurrence using germinal center kinase-like kinase. Oncotarget. 2016 Aug 02; 7(31):49765-49776.
-
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2016 07 20; 34(21):2484-92.
-
Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1). Expert Opin Ther Pat. 2016; 26(4):523-8.
-
Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. Cell Rep. 2015 Aug 25; 12(8):1300-13.
-
A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study. Neuro Oncol. 2015 Feb; 17(2):303-11.
-
Identification of p38? as a therapeutic target for the treatment of S?zary syndrome. J Invest Dermatol. 2015 Feb; 135(2):599-608.